PCV13-Serotype Breakthrough Pneumococcal Disease in Infants Receiving High-Valency Conjugate Vaccines: Population-Level Modeling in France
Implementation of PCV15 in a 2 + 1 regimen could reduce bIPD incidence due to all PCV13 serotypes in infants, whereas PCV20 in a 2 + 1 regimen may lead to substantial increases in bIPD cases from PCV13 serotypes in infants. PCV20 in a 3 + 1 regimen could potentially lead to a resurgence of bIPD from PCV7 serotypes in infants.
Authors
- Tufail Malik (ORCID: https://orcid.org/0000-0003-0196-0057)
- Rachel J. Oidtman (ORCID: https://orcid.org/0000-0003-1773-9533)
- Kristen A. Feemster (ORCID: https://orcid.org/0000-0003-0822-5688)
- Jessica Weaver (ORCID: https://orcid.org/0000-0002-9861-3328)
- Natalie Banniettis
- Priscilla Velentgas (ORCID: https://orcid.org/0009-0007-4764-2595)
- Kevin Bakker (ORCID: https://orcid.org/0000-0002-7084-9291)
- Giulio Meleleo
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Decision Sciences (United States) (US)
- Wolfram Research (United States) (US)
Publication Details
- Journal
- Infectious Diseases and Therapy
- Published
- 2025-03-19
- DOI
- https://doi.org/10.1007/s40121-025-01123-4
- Citations
- 3
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 4.06
Funders
- Merck